Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study.

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol (2016) 0.90

Chemotherapy-induced peripheral neuropathy: an update on the current understanding. F1000Res (2016) 0.78

An integrated perspective on diabetic, alcoholic, and drug-induced neuropathy, etiology, and treatment in the US. J Pain Res (2017) 0.78

Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC Cancer (2017) 0.75

Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther (2016) 0.75

Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst (1990) 3.09

Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol (2006) 2.93

Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs (2003) 2.35

Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med (1995) 2.29

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996) 2.17

Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol (2006) 1.93

Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol (2012) 1.85

Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol (2006) 1.67

Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther (2011) 1.62

Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol (2008) 1.40

Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev (2014) 1.33

Mechanism of taxane neurotoxicity. Breast Cancer (2004) 1.26

Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat (2010) 1.19

Toxic neuropathy in patients with pre-existing neuropathy. Neurology (2003) 1.11

Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol (2015) 0.94

Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol (2004) 0.88

Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care (Engl) (2007) 0.79

Pathogenesis of painful diabetic neuropathy. Pain Res Treat (2014) 0.78

Hyperglycemia- and neuropathy-induced changes in mitochondria within sensory nerves. Ann Clin Transl Neurol (2014) 0.78

Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat (2013) 0.77

Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study. Support Care Cancer (2015) 0.76

Illness perception is a strong parameter on anxiety and depression scores in early-stage breast cancer survivors: a single-center cross-sectional study of Turkish patients. Support Care Cancer (2017) 0.75